More data prompt NICE change of heart for BMS/Otsuka's Abilify
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, says it will recommend Abilify (aripiprazole) for patients aged between 15 and 17 with schizophrenia, thanks to more information comparing the drug with other antipsychotics used regularly on the NHS.